Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Goldstar to begin diamond-drilling in early June on its Lake George Property in New Brunswick, Canada

2018-05-22 globenewswire
MONTRÉAL, QUÉBEC, May 22, 2018 (GLOBE NEWSWIRE) -- Goldstar Minerals Inc. (“Goldstar” or the “Company”) (TSX-V:GDM) is pleased to announce that the Company is putting the final touches on the targeting process and expects to soon begin its diamond drilling program on the Lake George Property, located in New Brunswick, Canada. Field crews are being mobilized and, once site preparation is completed, drilling is expected to begin in early June.
GDM GDMIF

0
Goldstar Minerals Announces Stock Option Grant

2018-05-17 globenewswire
MONTRÉAL, May 17, 2018 (GLOBE NEWSWIRE) -- Goldstar Minerals Inc. (TSX-V:GDM) (“Goldstar” or the “Company”) is pleased to announce that the Company has granted 5,287,292 stock options to directors, officers and service providers exercisable at $0.10. These options vest immediately and have a five-year term. These options are subject to regulatory and shareholder approval.
GDM GDMIF

0
BRIEF-Goldstar Minerals Announces Approval Of New Stock Option Plan

2018-05-10 reuters
* GOLDSTAR MINERALS INC - DIRECTORS APPROVED A NEW “ROLLING 10%” STOCK OPTION PLAN Source text for Eikon: Further company coverage: ([email protected])
GDM

0
Goldstar Minerals clôture son placement de droits

2018-05-09 globenewswire
MONTRÉAL, 09 mai 2018 (GLOBE NEWSWIRE) -- Société minière Goldstar - Goldstar Minerals Inc. (TSX‑V:GDM) (la “Société”) annonce la clôture de son placement de droits antérieurement annoncé. Aux termes de celui-ci, la Société émettra 14 006 548 actions ordinaires au prix de 0,05 $ l’action pour un produit brut total de 700 327,40 $.
GDM

0
Goldstar Minerals Closes Rights Offering

2018-05-09 globenewswire
MONTRÉAL, May 09, 2018 (GLOBE NEWSWIRE) -- Goldstar Minerals Inc. (TSX-V:GDM) (the “Company”) announces the closing of its previously announced rights offering (the “Offering”). Under the Offering, the Company will be issuing 14,006,548 common shares at $0.05 per share for aggregate gross proceeds of $700,327.40.
GDM

0
Goldstar completes permitting for diamond-drilling on its Lake George Property in New Brunswick, Canada

2018-04-11 globenewswire
MONTRÉAL, April 11, 2018 (GLOBE NEWSWIRE) -- Goldstar Minerals Inc. (“Goldstar” or the “Company”) (TSX-V:GDM) is pleased to announce that the permitting is now complete as all private landowners have been consulted with respect to the upcoming drilling program on its Lake George Property, located in New Brunswick, Canada. The Company expects to begin its second phase diamond drill program in early June, focusing its efforts on the Coyote and WLF gold zones.
GDM

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to TSXV:GDM / Goldstar Minerals Inc on message board site Silicon Investor.

ICSI,ETFC,RWIG,CPZR,SEBT,GDMN, MTMH Another Big Scam? Golden Maritime Resources -New IPO-